GoodRx Holdings (GDRX) Cash from Financing Activities (2019 - 2026)

GoodRx Holdings has disclosed Cash from Financing Activities across 8 years of filings, most recently posting -$16.3 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$16.3 million, up 84.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$145.9 million (up 48.17% YoY), and the FY2025 annual result was -$234.5 million, up 30.53% from the prior year.
• Cash from Financing Activities came in at -$16.3 million for Q1 2026 at GoodRx Holdings, down from -$12.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of -$864000.0 in Q2 2024 to a low of -$172.1 million in Q3 2024.
• The 5-year median for Cash from Financing Activities is -$16.3 million (2026), against an average of -$51.5 million.
• Across the five-year window, Cash from Financing Activities jumped 97.19% in 2024 and slumped 5794.44% in 2025, its largest moves.
• GoodRx Holdings' Cash from Financing Activities stood at -$4.8 million in 2022, then tumbled by 2524.43% to -$125.6 million in 2023, then surged by 97.19% to -$3.5 million in 2024, then slumped by 263.37% to -$12.8 million in 2025, then fell by 27.11% to -$16.3 million in 2026.
• The last three Cash from Financing Activities figures came in at -$16.3 million (Q1 2026), -$12.8 million (Q4 2025), and -$65.8 million (Q3 2025), per Business Quant data.